DNA damage responses have been proposed as a gatekeeper to block tumorigenesis. We identify unexpected mechanisms whereby ATM-mediated pathway interacts with NFkB inflammatory cascades, leading to upregulation of integrin-abb3 on chemoresistant tumor cells. The integrin-abb3 is responsible for impeding tumor-specific immune responses, linking chemoresistant niche with tumor immune evasion.
DNA damage checkpoint machineries serve as a gatekeeper to keep cellular and genetic integrity at steady-state. The activation of DNA damage repairing systems is frequently detected in precancerous and early tumor lesion, leading to cell cycle arrest and apoptosis by p53-dependent mechanisms. 1 Recent evidences have unveiled the role of tumor cells in the regulation of the biologic properties of stromal cells, endothelial cells, and host immunity in local microenvironments, leading to further tumor progression and a worse prognosis. 5, 6 Therefore, the acquisition of anticancer drug resistance may render tumor cells with the ability to modulate their microenvironments in a paracrine fashion, further enhancing survival signals and the progression of tumors. However, the molecular mechanisms regulating interplay between tumor cells and immune cells to create chemoresistant microenvironments remain largely obscure.
We recently found some unexpected aspects of DNA damage signals on anticancer drug resistance of tumor cells. The tumor cells acquired resistance to various chemotherapeutic drugs exhibit constitutive activation of sets of DNA damage signals, ATM and chk-2. The constitutive activation of ATM-mediated activation of DNA damage pathways is indispensable for triggering integrin-avβ3 induction on tumor cells. Furthermore, integrin-avβ3 on tumor cells facilitate the uptake of viable tumor cells by dendritic cells in RGD-dependent manner, by which crosspresentation of immunogenic antigens and induction of tumor-specific cytotoxic T lymphocytes are severely compromised at tumor microenvironments. 7 Overall, these findings provide novel mechanistic insights whereby cell intrinsic and environmental regulation of therapeutic responses may change the genetic profiles of tumor cells to activate distinct sets of DNA damage pathways, causing the induction of downstream mediators responsible for modulating tumor microenvironments and supporting further tumor progression by compromising endogenous host immunity.
Although the molecular machineries that ATM-mediated DNA damage responses cause integrin-avβ3 upregulation remain unresolved issue, unique genotoxic stress-induced systems mediated by ATMdependent DNA damage signals and NFkB-mediated inflammatory cascades, are required for inducing integrin-avβ3 on therapy-resistant tumor cells. 7 Consistent with these findings, previous study unveiled novel pathways in which ATM stimulates NFkB-mediated inflammatory signals in response to genotoxic stimuli such as cytotoxic drugs and irradiation. 8 Although Ashkenazi et al. recently suggested that acute phase of DNA damage signals could increase the susceptibility to apoptotic cell death of Hela cells through NEMO and TNFa-mediated pathways, 9 the same pathways may in turn contribute to increased cell survival when chemoresistant tumor cells manifest constitutive activation of ATM and NFkB. Since NFkB has been established as a critical sentinel linking inflammation with carcinogenic process, 10 chronic activation of DNA damage responses in tumor cells may be linked with inflammationassociated carcinogenesis. Moreover, the continuous activation of ATM and NFkB in chemoresistant tumors may be linked with induction of downstream effectors responsible for modifying tumor microenvironments such as integrin-avβ3, and promoting tumorigenic and metastatic potential. In these perspectives, we propose the novel pathways whereby chronic activation of ATM and NFkB renders tumor cells with the ability to downregulate antitumor immunosurveillance, at least in part through upregulation of integrin-avβ3 on tumor cells. In contrast, acute responses of DNA damage efficiently eliminate excessively damaged cells by activating p53-dependent pathways and antitumor innate immune responses (Fig. 1) .
Further elucidation and deep understanding of mechanisms linking DNA damage signals with inflammatory cascades and their impact on tumor microenvironments should explore new strategy to target tumors refractory to current anticancer regimens. 
